BioCryst Pharmaceuticals | BCRX - Actif À Court Terme





Actif À Court Terme Changement Date
Alnylam Pharmaceuticals USD 4.22B 168.65M 2026-03
BioCryst Pharmaceuticals USD 373.62M 30.72M 2026-03
Chugai Pharma JPY 1.54T 201.32B 2026-03
Daiichi Sankyo JPY 2.1T 218.5B 2025-12
DBV Technologies USD 246.7M 33.76M 2026-03
Enanta Pharmaceuticals USD 198.68M 5.65M 2025-12
Gilead Sciences USD 18.64B 1.25B 2026-03
GlaxoSmithKline GBP 17.76B 251M 2026-03
Glaxosmithkline GBP 17.76B 5.83B 2026-03
Incyte USD 5.48B 460.36M 2026-03
Ionis Pharmaceuticals USD 2.94B 52M 2026-03
Karyopharm Therapeutics USD 103.15M 13.4M 2025-12
Neurocrine Biosciences USD 2.44B 86.6M 2026-03
Novavax USD 850.82M 127.46M 2026-03
PTC Therapeutics USD 2.25B 19.94M 2026-03
Regeneron Pharmaceuticals USD 18.21B 187.3M 2026-03
Roche Holding CHF 38.73B 3.03B 2025-12
Sarepta Therapeutics USD 2.31B 228.06M 2026-03
Ultragenyx Pharmaceutical USD 657M 294M 2026-03
Vertex Pharmaceuticals USD 11.73B 529.3M 2026-03